坦索罗辛对膀胱癌患者膀胱灌注治疗后膀胱刺激征的改善效果

Improvement effect of tamsulosin on bladder irritative symptoms after bladder irrigation in patients with bladder cancer

目的 探讨坦索罗辛对膀胱癌患者膀胱灌注治疗后膀胱刺激征的初步疗效和安全性。方法 选择2018年8月1日至2021年7月31日收治的60例非肌层浸润性膀胱癌患者。所有患者均接受经尿道膀胱肿瘤电切术,术后行吉西他滨膀胱灌注治疗,随机分为研究组和对照组各30例。研究组患者于膀胱灌注治疗后开始口服坦索罗辛治疗(每天0.2 mg,连续7天);对照组患者膀胱灌注治疗后,不行任何干预。于膀胱灌注治疗第1、2、7天分别记录各组患者膀胱过度活动症症状评分(OABSS)和视觉疼痛模拟评分(VAS)、生活质量评分(QOL)。结果 治疗第1天、第2天,研究组OABSS均低于对照组,差异有统计学意义(P<0.05或0.01),治疗第7天,两组OABSS比较差异无统计学意义(P>0.05)。治疗第1天、第2天及第7天,研究组的VAS均低于对照组,差异有统计学意义(P<0.05或0.01)。治疗第2天,研究组QOL低于对照组,差异有统计学意义(P<0.01),治疗第1天、第7天,两组QOL比较差异无统计学意义(P>0.05)。研究组中有3例患者出现体位性低血压,无需特殊处理;对照组无不良反应。结论 坦索罗辛可改善膀胱癌患者电切术后膀胱灌注治疗后的膀胱刺激症状,提高患者生活质量。

Objective To investigate the preliminary efficacy and safety of tamsulosin on bladder irritative symptoms after bladder irrigation in patients with bladder cancer. Methods 60 patients with non muscle invasive bladder cancer admitted to hospital from August 1, 2018 and July 31, 2021 were selected. All patients underwent transurethral resection of bladder tumour(TURBt). After operation, they were given bladder irrigation by gemcitabine. All patients were randomly divided into study group and control group, with 30 cases in each group. After bladder irrigation, the study group were given oral tamsulosin(0.2 mg per day for 7 days), while the control group did not receive any intervention. And then, overactive bladder syndrome score(OABSS), visual analogue pain scale(VAS) and quality of life(QOL) score on the 1 st, 2 nd and 7 th day of bladder irrigation were recorded, respectively. Results On the 1 st and 2 nd day of treatment, the OABSS of the study group were all lower than those of the control group, and difference was statistically significant(P<0.05 or 0.01). On the 7 th day of treatment, there was no statistically significant difference on the OABSS between the two groups(P>0.05). On the 1 st, 2 nd and 7 th day of treatment, the VAS of the study group were all lower than those of the control group, and the difference was statistically significant(P<0.05 or 0.01). On the 2 nd day of treatment, the QOL of the study group was lower than that of the control group, and the difference was statistically significant(P<0.01). On the 1 st and 7 th day of treatment, there was no statistically significant difference in the QOL between the two groups(P>0.05). Three patients in the study group had postural hypotension without special treatment, and no adverse reactions in the control group were found. Conclusion Tamsulosin can improve bladder irritative symptoms after bladder irrigation on bladder cancer patients who undergo TURBt, and can improve patient’s quality of life.